Vilon (20mg)

Vilon Peptide

Vilon (or Lyslglutamic Acid) is a peptide with apparent immunomodulatory and anti-aging bioregulation potential. It is a short peptide with just two amino acids in length. Scientific research suggests it may potentially act to regulate the vascular system and encourage hemostasis. Its functions may be more widespread, with studies indicating its possible influence in reducing the prevalence and growth of spontaneous tumors. Advocate researchers like Dr. Vladimir Anisimov believe that the peptide may become more widespread in contemporary research within the context of geroprotection.

Specifications

Sequence Formula: H-Lys-Glu-OH

Molecular Formula: C₁₁N₂₁N₃O₅

Molecular Weight: 257.30g/mol

Synonyms: Lysylglutamate, normophthal, Lyslglutamic acid

Vilon Research

Vilon Peptide and Cancer Cells

Research findings in murine models suggest that Vilon may reduce the prevalence of cancer cells. Studies report that exposure to the peptide may have reduced tumor prevalence and inhibited growth in mice, warranting further examination within the context of chemotherapeutic research.[1]

Scientific studies reported mixed results when Vilon was combined with a platinum-based chemotherapeutic agent, with the anti-cancer potential of Vilon and its role in chemotherapy research remaining under active investigation. Scientists revealed that “Vilon stimulated apoptosis both in young and old rats, but the inhibitory effect of cyclophosphan was abolished in the presence of vilon in culture media.”[2]

Further research examined the potential impact of Vilon against placebo on urinary bladder cancer cell dynamics in murine models exposed to N-butyl-N-(4-hydroxybutyl)nitrosamine (BBNA) — a compound proposed to trigger bladder cancer cell formation.[3] Initial results indicated that Vilon may reduce cancer cell emergence, with 56% of Vilon-exposed models showing cancer cell development compared to 75.5% in the control group. The study also observed potential changes in the bladder mucosa of exposed models, including reduced frequency and severity of early cancerous and pre-cancerous alterations, fewer instances of hyperplasia, and a slower rate of malignant transformation — suggesting Vilon may delay or alter the transition from normal to malignant cellular states. The average number of tumors per Vilon-exposed mouse was also lower at 1.5 compared to 2.6 in controls, with tumor cells displaying a less aggressive growth pattern. These observations suggest Vilon may interfere with BBNA’s cancer-promoting mechanisms and may act as an immunomodulator, potentially inhibiting cancer initiation and progression in this model.

Vilon Peptide and Immunity

Studies examining Vilon expression suggest it may function as a potent chromatin structure regulator.[4] Research reported that Vilon exposure may lead to activation of chromatin unrolling, release of repressed genes, and activation of synthetic processes through reactivation of ribosomal genes in unrolled chromatin — without appearing to cause structural chromatin decondensation.

The research further suggests that Vilon may induce reactivation of silenced DNA genes. Chromatin exists in two principal states — heterochromatin and euchromatin — with genes in the heterochromatic state considered inaccessible for protein production. Chromatin condensation may occur through cellular aging and senescence, potentially explaining why cells and tissues lose functionality over time. The proposed ability of Vilon, in combination with other peptide bioregulators, to reactivate specific genes by unrolling heterochromatin may improve immune function in aged animal models.[5] Researchers reported that “peptide bioregulators Epitalon, Livagen, and Vilon [may] cause activation (deheterochromatinization) of chromatin in lymphocytes of [older research models].”

Interleukin-2 is considered vital in coordinating immune responses to microbial infection and may inhibit autoimmune reactions. Activation of interleukin-2 signaling represents one proposed action of Vilon in the spleen, with the peptide potentially restoring the immune system to a more effective state and activating lymphocytes and splenocytes to support natural defense against autoimmune activity.

Research suggests Vilon may enhance the propagation of CD5 T-cells in the thymus. CD5 is a recognized immunohistochemical marker for T-helper cells and cytotoxic CD8 T-cells, potentially playing a significant role in T-cell growth and differentiation within the thymus.[6] Researchers observed an apparent 78% rise in CD5 expression in thymic cells from murine models and a 45% elevation in embryonic thymic cells relative to controls — suggesting Vilon may influence thymic cell differentiation, guiding T-cell precursors toward CD4+ T-helper cell development. These cells are considered essential to the adaptive immune system, coordinating responses of other immune cells. Vilon appears to function specifically through reactivation of genes silenced by chromatin changes, without activating genes that would ordinarily be silent in the cells it modifies.

Vilon Peptide and the Kidneys, Heart

While Vilon’s influence on vasculature has not been extensively studied, available research suggests it may demonstrate activity within these organs. Research in murine models indicates that Vilon may alter the expression of more than 36 genes in the heart, with this number reportedly rising to 144 genes when combined with Epitalon — suggesting Vilon may influence cardiovascular gene expression trends and improve hemodynamic function. Research further suggests Vilon may reduce TGF-beta 1 concentrations in the kidneys and highly vascular organs, potentially increasing microvessel permeability[7] and improved hemostasis during kidney failure. Studies in diabetic research models additionally report that Vilon may support coagulation by enhancing antithrombin III anticoagulant levels and Protein C while simultaneously stimulating fibrinolysis, potentially reducing blood clot formation in clotting-prone conditions.[8]

Vilon Peptide and Cellular Aging

Exposure to Vilon appears to enhance contractile force and endurance within muscle tissue while potentially reducing cancer cell prevalence — two effects hypothesized in murine models to contribute to extended muscle cell longevity. Research suggests that early-stage Vilon exposure may have increased the longevity of observed animal research models, with the hypothesis proposing that later-stage introduction may reverse senescence in existing cells but may not replicate this effect for cells already eliminated through apoptosis. Early Vilon exposure in murine models appeared to confer a degree of protective stability, with many cells remaining viable for extended periods and retaining limited stem cell lines.[9]

A further study examined Vilon’s potential on tissue explants from murine models at various life stages — neonatal, juvenile, and mature.[10] The study speculates that Vilon may help preserve tissue structure and support cellular regenerative capacity and function, with effects appearing more pronounced in tissues from older animals — suggesting particular relevance for cellular aging and regeneration research. Research has additionally explored Vilon’s capacity to attenuate accelerated aging in murine thymus and spleen induced by low-level ionizing radiation,[11] with preliminary findings suggesting Vilon may partially counteract radiation-driven aging effects. This positions Vilon as a compound of interest for research into managing radiation-induced cellular aging in key immune organs such as the thymus.

Vilon’s proposed anti-aging effects extend to gastrointestinal function, where it appears to support enzyme activity in the GI tracts of aged murine models, potentially improving cell barrier function, reducing intestinal permeability, and enhancing resistance to disease. Vilon may also support nutrient absorption through improved glucose and glycine uptake, potentially contributing to improved cellular function and extended longevity. According to research by Dr. Vladimir N. Anisimov, the thymus and pineal glands are recognized as vital regulators of cellular aging.[12] Vilon is classified as a thymic peptide and appears to exert its primary effects on lymphocytes and other thymus-derived cells.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References